93 results
Page 3 of 5
424B3
87fei x22cjl206
14 Jul 20
Prospectus supplement
4:05pm
8-K
EX-99.1
zo3zd ymxm1bvx
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.1
mncppddf
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
uxojq1osbbjelbj
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.1
2qeol1y ciah74bhwx5
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.2
arofkcf31axo95jc9h
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
0iv4i4uy9vgn0j7g
13 Jan 20
Other Events
8:06am
8-K
EX-99.1
bww6oaocg65v6wi
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
kzpo1 vfs
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-99.1
j2106fnila1s8c
2 Dec 19
Other Events
5:18pm
8-K
EX-99.1
sng5agaq
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.2
ho0mwv 42
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
mf5s4gtv9
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
cez85 qpjymg9z
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
tokoc2nwpiqso
20 Nov 19
Other Events
7:05am
8-K
EX-99.2
uxg6fb3s ey3
20 Nov 19
Other Events
7:05am